Title |
Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study
|
---|---|
Published in |
Critical Care, September 2007
|
DOI | 10.1186/cc6119 |
Pubmed ID | |
Authors |
Anne-Cornélie JM de Pont, Jorrit-Jan H Hofstra, Derk R Pik, Joost CM Meijers, Marcus J Schultz |
Abstract |
In patients with suspected heparin-induced thrombocytopenia (HIT) who need renal replacement therapy, a nonheparin anticoagulant has to be chosen to prevent thrombosis in the extracorporeal circuit. Danaparoid, a low-molecular-weight heparinoid consisting of heparan sulphate, dermatan sulphate, and chondroitin sulphate, is recommended for systemic anticoagulation in patients with HIT. However, there are few data on the use of danaparoid in patients with acute renal failure, especially in patients dependent on renal replacement therapy such as continuous venovenous hemofiltration (CVVH). In the present study, we analyzed the pharmacokinetics and pharmacodynamics of danaparoid during CVVH in patients with suspected HIT. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Belgium | 1 | 3% |
Canada | 1 | 3% |
Unknown | 30 | 94% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 6 | 19% |
Researcher | 4 | 13% |
Student > Master | 4 | 13% |
Student > Bachelor | 3 | 9% |
Student > Postgraduate | 3 | 9% |
Other | 9 | 28% |
Unknown | 3 | 9% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 18 | 56% |
Mathematics | 2 | 6% |
Biochemistry, Genetics and Molecular Biology | 2 | 6% |
Nursing and Health Professions | 1 | 3% |
Economics, Econometrics and Finance | 1 | 3% |
Other | 3 | 9% |
Unknown | 5 | 16% |